ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease

Wu, Yichuan; Lin, Huanjia; Tao, Yuan; Xu, Ying; Chen, Jiaqi; Jia, Yijie*; Zheng, Zongji*南方医科大学
Frontiers in Pharmacology2022-9-16DOI: 10.3389/fphar.2022.967317
4被引14阅读
引用收藏
分享

摘要

Diabetic kidney disease (DKD) is one of the major causes of end-stage renal disease (ESRD). To evaluate the efficacy and safety of different types of mineralocorticoid receptor antagonists (MRAs) in diabetic kidney disease patients, we conducted this network meta-analysis by performing a systematic search in PubMed, MEDLINE, EMBASE, Web of Science, the Cochrane Library, and . A total of 12 randomized clinical trials with 15,492 patients applying various types of MRAs covering spironolactone, eplerenone, finerenone, esaxerenone, and apararenone were included. The efficacy outcomes were the ratio of urine albumin creatine ratio (UACR) at posttreatment vs. at baseline, change in posttreatment estimated glomerular filtration (eGFR) vs. at baseline, and change in posttreatment systolic blood pressure (SBP) vs. at baseline. The safety outcome was the number of patients suffering from hyperkalemia. High-dose finerenone (MD -0.31, 95% CI: -0.52, -0.11), esaxerenone (MD -0.54, 95% CI: -0.72, -0.30), and apararenone (MD -0.63, 95% CI: -0.90, -0.35) were associated with a superior reduction in proteinuria in patients with DKD. Regarding the change in eGFR, the results of all drugs were similar, and finerenone may have potential superiority in protecting the kidney. Compared with placebo, none of the treatments was associated with a higher probability of controlling systolic blood pressure during treatment. Moreover, spironolactone, esaxerenone, and 20 mg of finerenone presented a higher risk of hyperkalemia. This Bayesian network meta-analysis was the first to explore the optimal alternative among MRAs in the treatment of DKD and revealed the superiority of 20 mg of finerenone among MRAs in treating DKD.

学科与关键词

关键词
diabetic kidney disease (DKD)mineralocorticoid receptor antagonists (MRA)type2 diabeteshyperkalemianetwork meta-analysis (NMA)
相关
加载中…
  • Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
    Zhao, Li-Min; Zhan, Ze-Lin; Ning, Jie*; Qiu, Mei*Frontiers in Pharmacology, 2022, 12: 751496.被引 2
  • The effect of amiloride in decreasing albuminuria in patients with diabetic kidney diseases: a prospective, crossover, open-label study
    Li, Ruizhao; Xie, Zhiyong; Zhang, Li; Huang, Ying; Ma, Jianchao; Dong, Wei; Li, Zhilian; Chen, Yuanhan; Liang, Huaban; Wu, Yanhua; Zhao, Xingchen; Wang, Wenjian; Ye, Zhiming; Liu, Shuangxin; Shi, Wei; Liang, Xinling*RENAL FAILURE, 2021, 43(1): 452-459.被引 2
  • DAPAGLIFLOZIN DECREASES ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT TYPE 2 DIABETES: INSIGHTS FROM THE DAPA-CKD TRIAL
    Jong, Niels; Chertow, Glenn; Hou, Fan Fan; McMurray, John; Correa-Rotter, Ricardo; Rossing, Peter; Sjostrom, David; Stefansson, Bergur; Toto, Robert; Langkilde, Anna Maria; Wheeler, David C.; Heerspink, Hiddo Lambers58th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA), ELECTR NETWORK, 2021-06-05 To 2021-06-08.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-09-16
卷期
第 13 卷
页码
1021643
DOI
10.3389/fphar.2022.967317
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China; Natural Science Foundation of Guangdong [82000785, 81700730]; Guangzhou Science and Technology Project [2019A1515110661, 2017A030313555]; Outstanding Youth Development Scheme of Nanfang Hospital, Southern Medical University [202201010971]; Undergraduate Innovation and Entrepreneurship Training Program, Southern Medical University ( [2019J010]; [202112121007]

作者

  • W

    Wu, Yichuan (第一作者)

    southern med univ

  • L

    Lin, Huanjia

    southern med univ

查看全部 7 位作者收起作者
  • T

    Tao, Yuan

    southern med univ

  • X

    Xu, Ying

    southern med univ

  • C

    Chen, Jiaqi

    southern med univ

  • J

    Jia, Yijie (通讯)

    southern med univ

  • Z

    Zheng, Zongji (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417